This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.Novavax is expected to post a loss of $0.22 per share for the current quarter, representing a year-over-year change of +71.1%. Over the last 30 days, the Zacks Consensus Estimate remained unchanged.For the current fiscal year, the consensus earnings estimate of $2.67 points to a change of +317.1% from the prior year. Over the last 30 days, this estimate has changed +2.6%.For the next fiscal year, the consensus earnings estimate of $0.23 indicates a change of -91.3% from what Novavax is expected to report a year ago. Over the past month, the estimate has changed -50.4%.Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions.